Stop TB USA TB wire July 10, 2014

July 10, 2014
View Online | Subscribe | Unsubscribe
A REMINDER: The new “Friends of Stop TB USA” database will soon replace the old Newsletter mailing
list. The change will not be abrupt; however you will need to sign up as a Friend of Stop TB USA to
assure that you continue to receive the TB Wire and any or all of the other newsletters and email
alerts.
If you haven’t had a chance to complete the very short survey and sign up as a Friend of Stop TB USA,
we ask that you please take a moment and complete it here…
Please feel free to forward the TB Wire to others who may be interested. If the email is too large to
send, you can refer others to the Friends of Stop TB USA signup page where they can sign up to receive
it (and other Stop TB USA communications) directly. Stop TB USA can be found on Facebook and
Twitter! Links to our social media sites are on the header above. As always, suggestions and comments
are welcome and appreciated at [email protected].
WASHINGTON UPDATE
Thanks to Nuala Moore for the following updated information. Nuala is the Senior Legislative
Representative at the American Thoracic Society (ATS) Washington Office.
DOMESTIC TB FUNDING AND LEGISLATIVE UPDATE
The impending fall election is impacting the annual appropriations process, with the result that fiscal
year (FY) 2015 spending bills are now stalled in the Senate. Earlier this month, Senate Appropriations
Committee chair, Sen. Barbara Mikulski (D-MD), pulled the health spending bill, known as the LaborHealth and Human Services bill (Labor-HHS), from full Appropriations Committee action due to
disagreements over Republican-backed amendments on funding for the Affordable Care Act (ACA).
The Senate Labor-Health and Human Services Appropriations subcommittee, chaired by Sen. Harkin (DIA), passed the FY2015 health spending bill, which provides funding for CDC, including the TB program,
on June 10. The bill provides flat funding for CDC's domestic TB program, at $142.6 million, with actual
program level at $135 million. For the CDC overall, the bill provides $7.054 billion, an increase of $170.9
million, or about 2.3 percent, from the FY2014 level. It is unclear when the bill will be considered by the
full Senate Appropriations Committee and the full Senate.
The House Labor-HHS-ED subcommittee, chaired by Rep. Kingston (R-GA), has not scheduled a vote.
There is a strong chance that Congress will run out of time before the start of fiscal year 2015 on
October 1 and will have to pass temporary spending measures extending current funding into fiscal year
2015.
GLOBAL FUNDING
The House FY2015 Foreign Operations bill proposes to flat-fund USAID's global tuberculosis program at
the FY2014 level of $236 million. The Senate bill proposes a funding cut of $11 million, or just under 5%,
to the program, for a proposed FY2015 funding level of $225 million. Although we are disappointed that
the Senate proposed a cut to the program, both proposals are considerably better than the President's
FY2015 budget for the program, which is a $45 million, or 19% funding cut, which would reduce the
program's funding down to $191 million.
TB REAUTHORIZATION BILL
Legislation sponsored by Rep. Gene Green (D-TX) to renew the domestic TB program will be introduced
within the next few months. The bill will authorize increased funding for the domestic TB program.
ANNOUNCEMENTS
STOP TB USA
STOP TB USA COORDINATING BOARD VACANCY
Stop TB USA currently has a vacancy on the Coordinating Board. The Board consists of the Officers of the
Partnership, 10 or more additional members from the general Partnership membership, and ex officio
members (a representative of the American Thoracic Society, the Director of the Division of Tuberculosis
Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease
Control and Prevention, and the President of the National Tuberculosis Controllers Association). The
Board is responsible for overall policy and direction of the Partnership and approval, leadership,
direction and monitoring of the implementation of the Partnership’s Annual Work Plan.
The current vacancy is for a member who has policy, education and resource mobilization experience.
Please email [email protected] by July 23 rd , if interested
HIGHLIGHTED TB REPORTS/UPDATES
STOP TB PARTNERSHIP
Apathy in TB fight: The Economist Intelligence Unit
A new report on tuberculosis calls for raising the profile of TB, fight apathy and lack of compelling
ambition in addressing the disease. The report 'Ancient enemy, modern imperative: A time for greater
action against tuberculosis' by the Economist Intelligence Unit, supported by Janssen, a pharmaceutical
company producing TB drugs, also suggests finding and treating people where they live. The report
examines the state of the TB challenge, barriers to further progress, and how efforts need to evolve.
Dr Lucica Ditiu, Executive Secretary of the Stop TB Partnership, explains in the report that TB has been
met with apathy, "It is like an orphan. It has been neglected even in countries with a high burden and
often forgotten by donors and those investing in health interventions." Full story here.
WORLD HEALTH ORGANIZATION (WHO)
Emerging Bacterial Pathogens Unit, TB Supranational Reference Laboratory
1st Course on Molecular Diagnosis of Drug Resistant TB (First come first served, maximum 10
participants)10-15 Nov 2014
The Emerging Bacterial Pathogens Unit of Fondazione Centro San Raffaele (FCSR) in Milan, Italy is
organising a training course on molecular diagnosis of drug resistant TB. The training course, with
theoretical and practical sessions, will review all techniques currently endorsed by WHO for the rapid
diagnosis of tuberculosis and detection on antibiotic resistance as well as advanced molecular
innovations (Single nucleotide polymorphisms, whole genome sequencing). Participants will also
practice to identify resistances using sequencing thanks to the help of the sequencing platform.
This five-day course focuses on developing knowledge and skills needed for a successful implementation
and optimal utilization of new TB diagnostic tools.
For more information and registration please visit:
http://whocctblab.fondazionesanraffaele.it/forum.html#/20140616/1st-course-on-molecular-diagnosisof-drug-res-2-4015571/
RESULTS
Brazilian soccer champ and TB
http://www.goal.com/en-ng/news/4105/world-cup-2014/2014/07/03/4934411/ive-overcometuberculosis-i-can-overcome-this-thiago-silva
NATIONAL INSTITUTES FOR HEALTH (NIH)
NIH Scientists Establish Proof-of-Concept for Host-Directed Tuberculosis Therapy
In a new study published in Nature, NIH scientists describe a new type of tuberculosis (TB) treatment
that involves manipulating the body’s response to TB bacteria rather than targeting the bacteria
themselves, a concept called host-directed therapy. This strategy could be of particular benefit to
people infected with drug-resistant TB strains who have limited options for effective antibiotics.
For more information, visit:
http://www.niaid.nih.gov/news/newsreleases/2014/Pages/HostDirectedTBtherapy.aspx.
NATIONAL ASSOCIATION OF COUNTY AND CITY HEALTH OFFICIALS (NACCHO)
NACCHO has released the 2014 Forces of Change survey containing new findings on the forces that
affect change in our nation’s local health departments (LHDs). Economic forces, health reform, and
health department accreditation are among the greatest contributors to change.
Findings from the survey are presented in five research briefs: Local Health Department Budget Cuts and
Job Losses; Changes in Local Health Department Services; Billing for Clinical Services; Role of Local
Health Departments as Navigators;and Local Health Department Accreditation
Highlights: LHDs continue to experience budgetary challenges. Almost one-third of LHDs (28%) reported
a lower budget in 2013 than the prior fiscal year and a similar proportion (29%) expect budget cuts to
continue into the next fiscal year. LHDs also continue to lose jobs; since 2008, LHDs have collectively lost
48,300 jobs due to layoffs and attrition. These budget realities as well as the choices LHDs are making
about their role in the changing healthcare environment have affected the scale and scope of services
LHDs provide. In 2013, LHDs reported more expansions than reductions in population-based services,
such as population-based primary prevention services. With the exception of immunization (where LHDs
reducing services greatly outnumber those expanding them), similar proportions of LHDs reported
expansions and reductions in clinical services, such as chronic disease screening and treatment.
Most LHDs (81%) are seeking to bolster revenue by increasingly billing public and private third-party
payers for clinical services they provide. Many previously uninsured people gained coverage under the
Patient Protection and Affordable Care Act, but the limited role LHDs played in helping community
members gain this coverage illustrates a missed opportunity to improve access to healthcare. Few LHDs
(17%) served as navigators, a formal role responsible for enrolling people in health insurance programs
available through a state or federal health exchange or marketplace. More LHDs assisted in an unofficial
capacity, almost always without financial support.
Lastly, more LHDs have been formally engaged in the Public Health Accreditation Board’s voluntary
accreditation program. In 2014, one percent of LHDs have achieved accreditation and 11 percent have
submitted an application or Statement of Intent, nearly double the level of engagement measured in
2013. Accreditation in LHDs will provide the pathways to ensure accountability, consistency, better
synergy between community needs and public health services, and improved performance.
Visit www.naccho.org/topics/research/forcesofchange to learn how economic and political forces are
changing local public health.
THE UNION E-NEWS
The Union participates in summit to advance TB and HIV care in Latin America ...
Roll-out of new TB drug must be handled with care...
Global Drug-Resistant TB Initiative (GDI) holds first Core Group meeting...
TB and TB-HIV late-breakers in Barcelona: submit abstracts by 31 July...
Public Health Action seeks new EIC: Apply by 15 August...
To better serve our whole community, the entire Union website is now available in all three official
languages: English , French and Spanish
New leaders join The Union: The Union is pleased to announce the recent appointment of three new
members of its leadership team: Dr Adam M Karpati, Senior Vice President for Public Health (based in
New York); Dr Ajay Kumar, Deputy Director, Department of Research (based in Bangalore); and Mr
Matthew Coghlan, Director of The Union Asia Pacific Office (based in Singapore). Read more. . .
NATIONAL PREVENTION INFORMATION NETWORK (NPIN):
These reports have been discontinued as of the end of June by the CDC.
United States; India “Research May Yield New Ways to Treat Antibiotic-Resistant TB” Infection Control
Today (06.30.2014)
Infection Control Today reported that to find treatment for drug-resistant TB, researchers from the
United States and India have modified the anti-TB drug rifampicin to create a new compound, 24desmethylrifampicin. The new drug has greater antibacterial activity than rifampicin in treating
multidrug-resistant TB (MDR TB). The researchers used genetic modification and synthetic drug
development to make the new compound. They have only developed the compound in the laboratory
and is not yet available commercially. The drug requires additional development and testing before it
can be considered ready to be used for humans. The researchers used their understanding of the
process of how drug resistance develops when the bacterial RNA polymerase enzymes mutate. They
then modified the drug so it could bind to the mutated enzyme and be effective. Since rifampicin is such
an important drug in TB treatment, the researchers anticipate using the technology to create additional
antibiotics to treat rifampicin-resistant TB disease as well as other serious diseases. According to Taifo
Mahmud, a professor in the College of Pharmacy at Oregon State University and an author of the study,
“Understanding this whole process should allow us to create not just this one, but a range of different
analogs that can be tested for their efficacy as new antibiotics.”
The full report, “Modification of Rifamycin Polyketide Backbone Leads to Improved Drug Activity Against
Rifampicin-Resistant Mycobacterium tuberculosis,” was published online by the Journal of Biological
Chemistry, (2014; doi:10.1074/jbc.M114.572636). Read Full Article
Global:
INDIA: “Patients to Be Screened for Extensively Drug-Resistant TB at CMCH”, R. Sairam, The Hindu
(06.16.2014)
The Hindu reported that as of July 1, Coimbatore Medical College Hospital (CMCH) will begin
immediately testing all multidrug-resistant (MDR) TB patients for extensively drug-resistant (XDR) TB
when they request treatment. MDR TB is resistant to the first-line TB drugs isoniazid and rifampicin,
while XDR TB is resistant to those drugs as well as second-line drugs. The hospital now is equipped to
conduct the cartridge-based nucleic acid amplification test to diagnose MDR TB. At present, CMCH
screens MDR TB patients for XDR TB after six months of treatment. Intermediate Reference Laboratory
in Kerala conducts the XDR TB tests and the results take three months to process. According to a senior
official in the TB Directorate, XDR TB has a 25-percent mortality rate and a mortality rate as high as 50–
70 percent in HIV/TB-coinfected patients, even for patients who start treatment in the early stages of
the disease. With the earlier XDR TB testing, clinicians will receive earlier diagnoses, at three months
rather than nine months. This means XDR TB treatment could begin earlier, thus improving patients’
chances of survival. The TB Directorate official encourages private doctors with TB patients to use the
facility free of charge. Read Full Article
SOUTH AFRICA:
“SA Mine TB Rate Highest in World” IOL News (06.19.2014)
SAPAIOL News reported that Health Minister Aaron Motsoaledi announced that for every accidentrelated death among South African miners, nine miners died from TB. Motsoaledi stated South African
miners had the highest TB incidence of “any working population in the world.” In addition to 500,000
mine workers, TB also affected their 230,000 partners and 700,000 children. According to Motsoaledi,
59,400 orphans were “in care” because their parents had died from TB. Although unions typically
focused on mining fatalities related to accidents, Motsoaledi emphasized that TB deaths were much
more frequent among miners. Compared to 167 accident-related deaths in 2009, there were 24,590 TB
infections among miners and 1,598 deaths. According to Motsoaledi, 41,810 South African miners (1
percent of South Africa’s total population) had active TB infections each year, which accounted for 8
percent of the nation’s total cases. He noted that accidents killed 80 miners in the gold mining industry
in 2009, but TB caused 17,591 infections and 1,143 deaths.
Motsoaledi warned that multidrug-resistant TB (MDR TB) infections, which resulted in “huge economic
impact,” were a serious problem in South Africa. South Africa has established nine MDR TB facilities
where infected people reside for 18 months while receiving treatment. The health ministry has
identified six high-impact mining districts in Gauteng, North West, Limpopo, and Free State A, and
deployed new diagnostic technology that would decrease MDR TB diagnosis time from a week to two
hours. The ministry also sent 1,534 “outreach” teams to perform primary healthcare tasks, including TB
care, in municipal wards. Motsoaledi urged members of parliament to “mobilize” their districts to
address TB in distressed mining communities. South Africa President Jacob Zuma announced in his State
of the Union address the formation of an inter-ministry committee to assist with revitalizing the mining
communities. Read Full Article
INDIA: “Private Doctors Report 1,305 TB Cases Over 2 Years”
Umesh Isalkar, Times of India (06.23.2014)
According to the Times of India, an improvement in the reporting of TB cases by private physicians in the
city of Pune, located in Maharshtra, India, is assisting the Pune Municipal Corporation (PMC) in better
understanding the impact of the disease, which will lead to a stronger healthcare system for the state.
The Union health ministry issued a mandate on May 7, 2012, requiring healthcare providers to report all
TB cases, and Pune physicians began reporting cases by the end of May 2012. An increase in reported
cases can be seen, with 643 cases reported for 2013 compared with 432 cases for 2012. Private
physicians continue to increase their reporting, with a total of 230 cases reported this year between
January and April, in addition to an average of approximately 300 cases reported each month in civic
hospitals. Read Full Article
SOUTH AFRICA:
“Reducing Tuberculosis Among HIV-Infected Patients”
University World News (Africa Edition) (06.20.2014)
University World News reported on a study of isoniazid preventive therapy (IPT) and antiretroviral
therapy (ART) to prevent TB. TB is the greatest cause of morbidity and mortality in HIV-positive
individuals in Africa. Researchers at the University of Cape Town, South Africa, led by Dr. Molebogeng
Rangaka conducted a trial of IPT with HIV patients on ART at a Cape Town clinic with assistance from
Médicins Sans Frontières clinic staff and Western Cape provincial government. The researchers
conducted a placebo-controlled randomized trial with 1,329 HIV-positive individuals on ART at a
provincial Department of Health clinic in Khayelitsha. The results showed that TB risk was significantly
reduced after 12 months of isoniazid, and the drug was well tolerated. TB incidence was reduced by 37
percent. Moreover, the results proved the efficacy and safety of IPT in individuals on ART. According to
Gary Maartens, a professor at the University of Cape Town, it is well known that IPT reduces TB risk In
HIV-positive individuals who are not on ART, but it was not known whether IPT would provide additional
benefits and would be safe in patients on ART.
The results also showed that IPT benefitted both people who had positive TB skin tests (TST) and those
who did not. South Africa’s National Department of Health has already modified policy based on the
study findings. The full report, “Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis: A
Randomised Double-Blind, Placebo-controlled Trial,” was published online in the journal Lancet (2014;
doi:10.1016/S0140-6736(14)60162-8). Read Full Article
NEW RESOURCES
FIND TB RESOURCES Highlight of the Month
This month's highlight is Adherence to MDR-TB Treatment: The 5 A's of Patient Support from the U.S.
Agency for International Development (USAID) and TB Care II. This online course discusses key principles
and steps to facilitate treatment adherence for patients with MDR TB. The five A's presented in the
course are: assess, advise, agree, arrange, and assist.
Training Package on Xpert MTB/RIF, from the Global Laboratory Initiative.
Shelters and TB: What Staff Need to Know, Second Edition, from the Curry International TB Center
TB & Me: The Effects of TB, from Médecins Sans Frontières.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
Updated TB Self-Study Modules Available
JOURNAL ARTICLES
June 18 through July 2nd
Addiction. 2014 Jun 24. doi: 10.1111/add.12671. [Epub ahead of print]
Efficacy of brief motivational interviewing on smoking cessation at tuberculosis clinics in Tshwane,
South Africa: a randomised controlled trial.Louwagie GM, Okuyemi KS, Ayo-Yusuf OA.
Adv Drug Deliv Rev. 2014 Jun 30;73C:140-161. doi: 10.1016/j.addr.2014.05.004. Epub 2014 May 10.
Nanomedicines in the future of pediatric therapy.Sosnik A, Carcaboso AM.
AIDS. 2014 Jun 19;28(10):1463-72. doi: 10.1097/QAD.0000000000000278.
Performance of symptom-based tuberculosis screening among people living with HIV: not as great as
hoped.Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA.
AIDS. 2014 Jun 6 [Epub ahead of print]
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on
combination antiretroviral therapy: a phase I/II, randomized trial. THACHER EG, Cavassini M, Audran R,
Thierry AC, et al.
PubMed: www.amedeo.com/p2.php?id=24911353&s=tb&pm=2
AIDS Res Hum Retroviruses. 2014 Jul;30(7):644-647. Epub 2014 Jun 10.
Short Communication: Circulating Plasma HIV-1 Viral Protein R in Dual HIV-1/Tuberculosis
Infection.Toossi Z, Liu S, Wu M, Mayanja-Kizza H, Hirsch CS.
Am J Health Behav. 2014 Jul;38(4):501-9. doi: 10.5993/AJHB.38.4.3.
Poverty and substance use in South African tuberculosis patients.Louwagie GM, Wouters E, Ayo-Yusuf
OA.
Am J Epidemiol. 2014 Jul 1;180(1):103-10. doi: 10.1093/aje/kwu095. Epub 2014 May 14
Cirrhosis as a risk factor for tuberculosis infection-a nationwide longitudinal study in taiwan.Lin YT, Wu
PH, Lin CY, Lin MY, Chuang HY, Huang JF, Yu ML, Chuang WL.
Am J Respir Crit Care Med. 2014 Jun 30. [Epub ahead of print]
MAIT Cell Function is Modulated by PD-1 Signaling in Patients with Active Tuberculosis.Jiang J, Wang X,
An H, Yang B, Cao Z, Liu Y, Su J, Zhai F, Wang R, Zhang G, Cheng X.
Getting personal: Perspectives on individualized treatment duration in M/XDR-TB.Heyckendorf J, Olaru
ID, Ruhwald M, Lange C.
Am J Respir Crit Care Med. 2014 Jul 1;190(1):9-18.
Tuberculosis, Pulmonary Cavitation, and Matrix Metalloproteinases.Ong CW, Elkington PT, Friedland JS.
Antimicrob Agents Chemother. 2014 Jun 23. pii: AAC.01418-13. [Epub ahead of print]
The population pharmacokinetics of Bedaquiline (TMC207), a novel anti-tuberculosis drug.McLeay SC,
Vis P, van Heeswijk RP, Green B.
1,4-azaindole: potential drug candidate for the treatment of tuberculosis.Chatterji M, Shandil R,
Manjunatha MR, Solapure S, Ramachandran V, Kumar N, Saralaya R, Panduga V, Reddy J, K R P, Sharma
S, Sadler C, Cooper CB, Mdluli K, Iyer PS, Narayanan S, Shirude PS.
Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Anti-Tuberculosis Drug PA-824
with Concomitant Lopinavir/Ritonavir, Efavirenz, or Rifampin.Dooley KE, Luetkemeyer AF, Park JG, Allen
R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS
Clinical Trials Group (ACTG) A5306 Study Team.
Antimicrob Agents Chemother. 2014 Jul;58(7)
Pharmacokinetic and Pharmacodynamic Evaluation of AZD5847 in a Mouse Model of
Tuberculosis.Balasubramanian V, Solapure S, Shandil R, Gaonkar S, Mahesh KN, Reddy J, Deshpande A,
Bharath S, Kumar N, Wright L, Melnick D, Butler SL.
Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and
Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6.Court MH, Almutairi
FE, Greenblatt DJ, Hazarika S, Sheng H, Klein K, Zanger UM, Bourgea J, Patten CJ, Kwara A.
Reduced Emergence of Isoniazid Resistance with Concurrent Use of Thioridazine against Acute Murine
Tuberculosis.Dutta NK, Pinn ML, Karakousis PC.
Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous
Necrotic Granulomas.Irwin SM, Gruppo V, Brooks E, Gilliland J, Scherman M, Reichlen MJ, Leistikow R,
Kramnik I, Nuermberger EL, Voskuil MI, Lenaerts AJ.
In Vitro Activity of AZD5847 against Geographically Diverse Clinical Isolates of Mycobacterium
tuberculosis.Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy VK,
Rodrigues C, Hoffner S.
The T2 Mycobacterium tuberculosis Genotype, Predominant in Kampala, Uganda, Shows Negative
Correlation with Antituberculosis Drug Resistance.Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe
BB, Okee M, Joloba ML, Cobelens FG.
Apollo Medicine, Available online 11 June 2014
Newer diagnostic methods in tuberculosis detectionSuneetha Narreddy, Sujit Muthukuru
BMC Infect Dis. 2014 Jun 27;14(1)
Clinical and epidemiological characteristics of individuals resistant to M. tuberculosis infection in a
longitudinal TB household contact study in Kampala, Uganda.Ma N, Zalwango S, Malone LL, Nsereko M,
Wampande EM, Thiel BA, Okware B, Igo RP Jr, Joloba ML, Mupere E, Mayanja-Kizza H, Boom WH, Stein
CM.
Interpreting measures of tuberculosis transmission: a case study on the Portuguese population.Lopes JS,
Rodrigues P, Pinho ST, Andrade RF, Duarte R, Gomes MG.
BMC Public Health. 2014 Jun 18;14.
'Complex' but coping: experience of symptoms of tuberculosis and health care seeking behaviours - a
qualitative interview study of urban risk groups, London, UK.Craig GM, Joly LM, Zumla A.
BMC Med. 2014 Jun 18;12(1):101. doi: 10.1186/1741-7015-12-101.
Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to
adenosine deaminase and unstimulated interferon-γ in a high burden setting: a prospective
study.Pandie S, Peter JG, Kerbelker ZS, Meldau R, Theron G, Govender U, Ntsekhe M, Dheda K, Mayosi
BM.
BMC Microbiol. 2014 Jun 22;14:165. doi: 10.1186/1471-2180-14-165.
Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains
isolated in Thailand.Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S.
BMJ Case Rep. 2014 Jun 26;2014. pii: bcr2013200714. doi: 10.1136/bcr-2013-200714. 49.
Laparoscopic management of midgut malrotation and tuberculous peritonitis in an adolescent boy.Patel
RV, Jackson P, Zani A, De Coppi P.
Chest. 2014 Jun 26. doi: 10.1378/chest.14-0626. [Epub ahead of print]
Rapid Detection of Mycobacterium Tuberculosis Using a Novel Ultra-Fast Chip-Type Real-Time PCR
System.Lee SH, Kim SW, Lee S, Kim E, Kim DJ, Park S, Lee EJ, Lee SY, Lee JS, Lim CS, Kim WK, In KH.
Clin Infect Dis. 2014 Jun 30. pii: ciu506. [Epub ahead of print]
Transforming the fight against tuberculosis: Targeting catalysts of transmission.Dowdy DW, Azman AS,
Kendall EA, Mathema B.
Clin Microbiol Infect. 2014 Jun 19. doi: 10.1111/1469-0691.12726. [Epub ahead of print]
Role of casual contacts in the recent transmission of tuberculosis in settings with high disease
burden.Wang W, Mathema B, Hu Y, Zhao Q, Weili J, Xu B.
Clin Microbiol Infect. 2014 Jun 18. doi: 10.1111/1469-0691.12725. [Epub ahead of print]
Genotypic characterization and historical perspective of Mycobacterium tuberculosis among older and
younger Finns, 2008-2011.Smit PW, Haanperä M, Rantala P, Couvin D, Lyytikäinen O, Rastogi N, Ruutu P,
Soini H.
Clin Pediatr (Phila). 2014 Jun 26. pii: 0009922814540040. [Epub ahead of print]
Interferon-γ Release Assay for the Diagnosis of Latent Mycobacterium tuberculosis Infection in Children
Younger Than 5 Years: A Meta-Analysis.Ge L, Ma JC, Han M, Li JL, Tian JH.
Curr Diab Rep. 2014 Jul;14(7):505. doi: 10.1007/s11892-014-0505-1.
Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A
systematic review.Jørgensen ME, Faurholt-Jepsen D.
Curr Drug Deliv. 2014 Jun 19. [Epub ahead of print]
Mycobacterium tuberculosis Treatment Modalities and Recent Insights.Sukhithasri V, Vinod V, Varma S,
Biswas R.
Curr Opin Infect Dis. 2014 Jun 23. [Epub ahead of print]
Tuberculosis in solid organ transplant candidates and recipients: current and future
challenges.Subramanian AK.
Diagn Cytopathol. 2014 Jun 28. doi: 10.1002/dc.23190. [Epub ahead of print]
Tuberculosis revisited: Cytological perspective.Chatterjee D, Dey P.
Drugs . 2014 Jun 25. [Epub ahead of print]
Evolution of Drug Resistance in Tuberculosis: Recent Progress and Implications for Diagnosis and
Therapy.Trauner A, Borrell S, Reither K, Gagneux S.
Epidemiol Infect. 2014 Jul;142(7)
Mycobacterial bone marrow infections at a medical centre in Taiwan, 2001-2009.Lin SH, Lai CC, Huang
SH, Hung CC, Hsueh PR.
PCR to detect Mycobacterium tuberculosis in respiratory tract samples: evaluation of clinical
data.Rozales FP, Machado AB, De Paris F, Zavascki AP, Barth AL.
Micronutrient supplementation and T cell-mediated immune responses in patients with tuberculosis in
Tanzania.Kawai K, Meydani SN, Urassa W, Wu D, Mugusi FM, Saathoff E, Bosch RJ, Villamor E,
Spiegelman D, Fawzi WW.
Characterization of hepatitis C infection in tuberculosis patients in an urban city in the USA.Campo M,
Shrestha A, Oren E, Thiede H, Duchin J, Narita M, Crothers K.
Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990
to 2007.Bui TV, Meyssonnier V, Boelle PY, Che D, Antoine D, Jarlier V, Robert J.
Eur Radiol. 2014 Jun 28. [Epub ahead of print]
A high-resolution computed tomography-based scoring system to differentiate the most infectious
active pulmonary tuberculosis from community-acquired pneumonia in elderly and non-elderly
patients.Yeh JJ, Chen SC, Chen CR, Yeh TC, Lin HK, Hong JB, Wu BT, Wu MT.
Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a
TBNET consensus statement.Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC,
Chang KC, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C,
Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J,
Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A,
Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew WW, Zellweger JP, Cirillo DM;
TBNET.
Expert Opin Drug Saf . 2014 Jul;13(7):875-91. doi: 10.1517/14740338.2014.925443.
Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.Kargar M, Mansouri A,
Hadjibabaie M, Javadi M, Radfar M, Gholami K.
Gen Hosp Psychiatry. 2014 Jul-Aug;36(4):451.. Epub 2014 Mar 17.
Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis.Sharma B, Handa R,
Nagpal K, Prakash S, Gupta PK, Agrawal R.
Infect Drug Resist. 2014 Jun 18;7:153-65. doi: 10.2147/IDR.S45090. eCollection 2014. Review.
Epidemiology and disease burden of tuberculosis in children: a global perspective.Seddon JA, Shingadia
D.
Infect Genet Evol . 2014 Jun 20. [Epub ahead of print]
Stranger in a strange land: Ibero-American strain of Mycobacterium tuberculosis in Tibet,
China.Mokrousov I, Jiao WW, Wan K, Shen A.
Int J Infect Dis. 2014 Jun 28 [Epub ahead of print]
Correlation analysis between single nucleotide polymorphisms of pulmonary surfactant protein A gene
and pulmonary tuberculosis in the Han population in China.Yang HY, Li H, Wang YG, Xu CY, Zhao YL, Ma
XG, Sun YP, Chen H.
Int J Infect Dis. 2014 Jul;24:37-9. doi: 10.1016/j.ijid.2014.03.1383. Epub 2014 May 2.Importance of
contrast-enhanced fluid-attenuated inversion recovery imaging to detect paradoxical expansion of
tuberculoma.Kim HJ.
Int J Tuberc Lung Dis. 2014 Jul;18(7)
ECMO: an alternative support for acute respiratory failure caused by tuberculosis?Cogliandro V,
Lapadula G, Bandera A, Muscatello A, Marcolin R, Abbruzzese C, Rona R, Gori A.
False-positive Xpert(®) MTB/RIF assays in previously treated patients: need for caution in interpreting
results.Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M.
Prevalence of Aspergillus sensitisation in pulmonary tuberculosis-related fibrocavitary disease.Dhooria
S, Kumar P, Saikia B, Aggarwal AN, Gupta D, Behera D, Chakrabarti A, Agarwal R.
A molecular transport medium for collection, inactivation, transport, and detection of Mycobacterium
tuberculosis.Daum LT, Choi Y, Worthy SA, Rodriguez JD, Chambers JP, Fischer GW.
Impact of changing diagnostic criteria for smear-positive tuberculosis: a cohort study in Malawi.Koole O,
Munthali L, Mhango B, Mpunga J, Glynn JR, Crampin AC.
Composite indicator: new tool for monitoring RNTCP performance in India.Bansal AK, Kulshrestha N,
Nagaraja SB, Rade K, Choudhary A, Parmar M, Nair SA, Dewan PK, Yadav R, Moonan PK, Kumar A.
Changes of FASH ultrasound findings in TB-HIV patients during anti-tuberculosis treatment.Heller T,
Wallrauch C, Brunetti E, Giordani MT.
A new predictive model for an improved respiratory isolation strategy in HIV-infected patients with
PTB.Carugati M, Schiroli C, Zanini F, Vanoni N, Galli M, Adorni F, Franzetti F.
Tuberculosis in the intensive care unit: a prospective observational study.Balkema CA, Irusen EM,
Taljaard JJ, Koegelenberg CF.
Mortality of tuberculosis patients during treatment in Israel, 2000-2010.Shuldiner J, Leventhal A,
Chemtob D, Mor Z.
Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter
regimens.Gospodarevskaya E, Tulloch O, Bunga C, Ferdous S, Jonas A, Islam S, Rahman M, Hussain MA,
Haque MN, Egwaga S, Gardiner E, PrayGod G, Islam MA, Mann GH, Wells WA, Squire SB.
Validation of indirect tuberculosis treatment adherence measures in a resource-constrained
setting.Mkopi A, Range N, Lwilla F, Egwaga S, Schulze A, Geubbels E, van Leth F.
Adherence to treatment and supervision for tuberculosis in a DOTS programme among pastoralists in
Uganda.Kisambu J, Nuwaha F, Sekandi JN.
Active case finding for tuberculosis among people who inject drugs on methadone treatment in Dar es
Salaam, Tanzania.Gupta A, Mbwambo J, Mteza I, Shenoi S, Lambdin B, Nyandindi C, Doula BI, Mfaume S,
Bruce RD.
Interferon-gamma release assays piloted as a latent tuberculous infection screening tool in Canadian
federal inmates.Schwartz IS, Bach PJ, Roscoe B, Majury A, Hopman WM, Ellis E, Garrahan T, Smith J,
Barkley R, Panaro L, Jamieson F, Froats C, Gemmill I, Wobeser WL.
Tuberculosis incidence and treatment completion among Ugandan prison inmates.Schwitters A, Kaggwa
M, Omiel P, Nagadya G, Kisa N, Dalal S.
Derivation of a tuberculosis screening rule for sub-Saharan African prisons.Harris JB, Siyambango M,
Levitan EB, Maggard KR, Hatwiinda S, Foster EM, Chamot E, Kaunda K, Chileshe C, Krüüner A, Henostroza
G, Reid SE.
Trends in childhood drug-resistant tuberculosis in South Africa: a window into the wider
epidemic?Schaaf HS, Hesseling AC, Rautenbach C, Seddon JA.
Teaching chest X-ray reading for child tuberculosis suspects.Seddon JA, Padayachee T, Du Plessis AM,
Goussard P, Schaaf HS, Lombard C, Gie RP.
J Antimicrob Chemother. 2014 Jun 23. pii: dku230. [Epub ahead of print]
Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium
tuberculosis.Gonzalo X, Drobniewski F, Hoffner S, Werngren J.
J Antimicrob Chemother. 2014 Jul;69(7):1834-43. doi: 10.1093/jac/dku080. Epub 2014 Apr 9.
Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS
response: RecA as a potential target for antibacterial drug discovery.Nautiyal A, Patil KN, Muniyappa K.
J Appl Microbiol. 2014 Jul;117(1):266-72. doi: 10.1111/jam.12508. Epub 2014 Apr 29.
Assessment of messenger RNA (mRNA) of Mycobacterium tuberculosis as a marker of cure in patients
with pulmonary tuberculosis.Montenegro RA, Guarines KM, Montenegro LM, Lira LA, Falcão J, Melo FL,
Santos FC, Nascimento AL, Zuzarte MS, Leite RC, Schindler HC.
J Chem Inf Model. 2014 Jun 26. [Epub ahead of print]
Are Bigger Datasets Better for Machine Learning? Fusing Single-Point and Dual-event Dose Response
Data For Mycobacterium tuberculosis.Ekins S, Freundlich JS, Reynolds RC.
J Clin Microbiol. 2014 Jul;52(7).
Prospective cross-sectional evaluation of the small membrane filtration method for diagnosis of
pulmonary tuberculosis.Jones-López E, Manabe YC, Palaci M, Kayiza C, Armstrong D, Nakiyingi L,
Ssengooba W, Gaeddert M, Kubiak R, Almeida Júnior P, Alland D, Dietze R, Joloba M, Ellner JJ, Dorman
SE.
Development and Clinical Evaluation of sdaA Loop-Mediated Isothermal Amplification Assay for
Detection of Mycobacterium tuberculosis with an Approach To Prevent Carryover
Contamination.Nimesh M, Joon D, Varma-Basil M, Saluja D.
Lowenstein-Jensen Selective Medium for Reducing Contamination in Mycobacterium tuberculosis
Culture.Kassaza K, Orikiriza P, Llosa A, Bazira J, Nyehangane D, Page AL, Boum Y 2nd.
Multicenter Feasibility Study To Assess External Quality Assessment Panels for Xpert MTB/RIF Assay in
South Africa.Scott L, Albert H, Gilpin C, Alexander H, DeGruy K, Stevens W.
Mixed Mycobacterium tuberculosis Complex Infections and False-Negative Results for Rifampin
Resistance by GeneXpert MTB/RIF Are Associated with Poor Clinical Outcomes.Zetola NM, Shin SS,
Tumedi KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C.
Whole-Genome-Based Mycobacterium tuberculosis Surveillance: a Standardized, Portable, and
Expandable Approach.Kohl TA, Diel R, Harmsen D, Rothgänger J, Walter KM, Merker M, Weniger T,
Niemann S.
J Control Release. 2014 Jun 28;184C:36-50. doi: 10.1016/j.jconrel.2014.04.009. Epub 2014 Apr 13.
Nanostructured drug delivery for better management of tuberculosis. Kaur IP, Singh H.
J Infect. 2014 Jun 26. [Epub ahead of print]
Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected
patients.Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E,
Goletti D.
Identifcation of differentially expressed long non-coding RNAs in CD4+ T cells response to latent
tuberculosis infection.Yi Z, Li J, Gao K, Fu Y.
IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children.Latorre I, Díaz J, Mialdea I,
Serra-Vidal M, Altet N, Prat C, Díez N, Escribano A, Casas I, Rodrigo C, Ausina V, Ruhwald M, Dominguez
J.
J Infect. 2014 Jun 23. [Epub ahead of print]
Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial
targets.Baumann R, Kaempfer S, Chegou NN, Oehlmann W, Loxton AG, Kaufmann SH, van Helden PD,
Black GF, Singh M, Walzl G.
CFP10 and ESAT6 aptamers as effective Mycobacterial antigen diagnostic reagents.Tang XL, Zhou YX, Wu
SM, Pan Q, Xia B, Zhang XL.
Association between tuberculosis recurrence and interferon-γ response during treatment.Thi-Le Hang
N, Matsushita I, Shimbo T, Hong LT, Tam DB, Lien LT, Thuong PH, Cuong VC, Hijikata M, Kobayashi N,
Sakurada S, Higuchi K, Harada N, Endo H, Keicho N.
J Infect Dis. 2014 Jun 18. pii: jiu347. [Epub ahead of print]
Central memory CD4 T cells are responsible for superior protection against tuberculosis of the
recombinant Bacillus Calmette-Guérin ΔureC::hly vaccine.Vogelzang A, Perdomo C, Zedler U, Kuhlmann
S, Hurwitz R, Gengenbacher M, Kaufmann SH.
J Infect Public Health. 2014 Jun 19. [Epub ahead of print]
Ultrasound-guided core biopsy in the diagnostic work-up of tuberculous lymphadenitis in Saudi Arabia,
refining the diagnostic approach. Case series and review of literature.Altuwairgi O, Baharoon S, Alkabab
Y, Alsafi E, Almoweqel M, Al-Jahdali H.
Intramedullary craniovertebral junction tuberculoma: An uncommon location of a common
diseaseRajendra S. Jain, Rahul Handa, Trilochan Srivastava, Swayam Prakash, Kadam Nagpal, Indu
Bhana, Pankaj K. Gupta
J Microbiol Methods. 2014 Jun 24. [Epub ahead of print]
Evaluation of real-time loop-mediated isothermal amplification (RealAmp) for rapid detection of
Mycobacterium tuberculosis from sputum samples.Li Y, Shi L, Pan A, Cao W, Chen X, Meng H, Yan H,
Miyoshi SI, Ye L.
J Nanosci Nanotechnol. 2014 Jul;14(7):4745-56. Review.
The role of nanotechnology in combating multi-drug resistant bacteria. Singh R, Smitha MS, Singh SP.
Lancet Volume 383, Issue 9934 , 14 June 2014
Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data Lixia
Wang,Hui Zhang,Yunzhou Ruan,Daniel P Chin,Yinyin Xia,Shiming Cheng,Mingting Chen,Yanlin
Zhao,Shiwen Jiang,Xin Du,Guangxue He,Jun Li,Shengfen Wang,Wei Chen,Caihong Xu,Fei Huang,Xiaoqiu
Liu,Yu Wang
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62639-2/fulltext
Measuring the effect of tuberculosis control: a step forward:Giovanni Battista Migliori, Giovanni Sotgiu
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60032-5/fulltext
Treating tuberculosis as a social disease;Mohsin Ali.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61063-1/fulltext
Lancet Infect Dis. 2014 Jul;14(7):563-71. doi: 10.1016/S1473-3099(14)70733-9. Epub 2014 May 5.
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly
diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebocontrolled trial.Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O,
Connolly C, Kapotwe V, Muwonge C, Massaga J, Sinkala E, Kohi W, Lyantumba L, Nyakoojo G, Luwaga H,
Doulla B, Mzyece J, Kapata N, Vahedi M, Mwaba P, Egwaga S, Adatu F, Pym A, Joloba M, Rustomjee R,
Zumla A, Onyebujoh P.
The Lancet Infectious Diseases, Volume 14, Issue 6, Pages 454 - 455, June 2014
Screening and treating tuberculosis in immigrants to the USA Nelson, R
Med Hypotheses. 2014 Jul;83(1)
Statin therapy may prevent development of tuberculosis in diabetic state.Banerjee D, Bhattacharyya R.
Big brains, meat, tuberculosis and the nicotinamide switches: co-evolutionary relationships with modern
repercussions on longevity and disease?Williams AC, Dunbar RI.
Microb Drug Resist. 2014 Jun 18. [Epub ahead of print]
Ofloxacin Resistance in Mycobacterium tuberculosis Is Associated with Efflux Pump Activity
Independent of Resistance Pattern and Genotype.Sun Z, Xu Y, Sun Y, Liu Y, Zhang X, Huang H, Li C.
N Engl J Med 2014; 370:2362-2365June 19, 2014.
Perspective: Tuberculosis Control in New York City — A Changing Landscape: Michelle Macaraig,
Dr.P.H., M.P.H., Joseph Burzynski, M.D., M.P.H., and Jay K. Varma, M.D.;
Pediatr Infect Dis J. 2014 Jun 18. [Epub ahead of print]
Diagnosis and Treatment of Tuberculosis among Children at an HIV Care Program in Dar es Salaam,
Tanzania.Adams LV, McQuillan T 3rd, Naburi H, Lyatuu G, Ippolito M, Saunders A, Kiravu A, Palumbo P,
von Reyn CF.
Pediatr Infect Dis J. 2014 Jul;33(7)
Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab.Cruz AT,
Karam LB, Orth RC, Starke JR.
Impact of Antiretroviral Therapy on Opportunistic Infections of HIV-infected Children in the Therapeutic
Research, Education and AIDS Training Asia Pediatric HIV Observational Database.Prasitsuebsai W,
Kariminia A, Puthanakit T, Lumbiganon P, Hansudewechakul R, Siew Moy F, Law M, Kumarasamy N,
Razali K, Sirisanthana V, Sohn AH, Chokephaibulkit K.
Pharmacoeconomics. 2014 Jul;32(7):617-26. doi: 10.1007/s40273-014-0159-5.
Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs.Diel R,
Lampenius N.
Pharmacoepidemiol Drug Saf. 2014 Jun 24. doi: 10.1002/pds.3665. [Epub ahead of print]
Prescription patterns for tuberculosis treatment and adherence to treatment guidelines: a populationbased study in Taiwan.Wang SI, Shen GH, Shi HC, Chiou SJ.
PLoS One. 2014 Jun 27;9(6) eCollection 2014.
Pros and cons of the tuberculosis drugome approach - an empirical analysis.Chen FC, Liao YC, Huang JM,
Lin CH, Chen YY, Dou HY, Hsiung CA.
Transcript levels of major interleukins in relation to the clinicopathological profile of patients with
tuberculous intervertebral discs and healthy controls.Liu C, Zhan X, Xiao Z, Fan Q, Deng L, Cui M, Xiong C,
Xue J, Xie X.
A comparison of tools used for tuberculosis diagnosis in resource-limited settings: a case study at
mubende referral hospital, Uganda.Muwonge A, Malama S, Bronsvoort BM, Biffa D, Ssengooba W,
Skjerve E.
Mycobacteria Counteract a TLR-Mediated Nitrosative Defense Mechanism in a Zebrafish Infection
Model.Elks PM, van der Vaart M, van Hensbergen V, Schutz E, Redd MJ, Murayama E, Spaink HP, Meijer
AH.
Analysis of 30 patients with acupuncture-induced primary inoculation tuberculosis.Liu Y, Pan J, Jin K, Liu
C, Wang J, Chen L, Chen L, Yuan J.
To Achieve an Earlier IFN-γ Response Is Not Sufficient to Control Mycobacterium tuberculosis Infection
in Mice.Vilaplana C, Prats C, Marzo E, Barril C, Vegué M, Diaz J, Valls J, López D, Cardona PJ.
Pleiotropic Effect of AccD5 and AccE5 Depletion in Acyl-Coenzyme A Carboxylase Activity and in Lipid
Biosynthesis in Mycobacteria.Bazet Lyonnet B, Diacovich L, Cabruja M, Bardou F, Quémard A, Gago G,
Gramajo H.
Biochemical Characterization of Quinolinic Acid Phosphoribosyltransferase from Mycobacterium
tuberculosis H37Rv and Inhibition of Its Activity by Pyrazinamide.Kim H, Shibayama K, Rimbara E, Mori
S.
Preventive Medicine , Available online 16 June 2014
Determinants of Bacillus Calmette–Guérin (BCG) vaccination among Québec children; J. Li, D. Menzies,
J.S. Landry, A. Benedetti, M.C.
Public Health Action; Volume 4, Number 2 - June 2014
Operational research leading to rapid national policy change: tuberculosis-diabetes collaboration in
India ; A. M. V. Kumar, S. Satyanarayana, N. C. Wilson, S. S. Chadha, D. Gupta, S. Nair, R. Zachariah, A.
Kapur, A. D. Harries
Management of previously treated tuberculosis patients in Kalutara district, Sri Lanka: how are we
faring?; S. C. Abeygunawardena, B. N. Sharath, R. Van den Bergh, B. Naik, N. Pallewatte, M. N. N.
Masaima
Investigation of presumptive tuberculosis cases by private health providers: lessons learnt from a survey
in Pakistan; R. Fatima, E. Qadeer, D. A. Enarson, S. G. Hinderaker, R. Harris, A. Yaqoob, A. Bassili;
Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi;
H. Kanyerere, A. Mganga, A. D. Harries, K. Tayler-Smith, A. Jahn, F. M. Chimbwandira, J. Mpunga;
Public Health Action Volume 4, Supplement 1
Tuberculosis case burden and treatment outcomes in children, adults and older adults, Vanuatu, 2007–
2011 ; M. Tagaro, A. D. Harries, B. Kool, S. Ram, K. Viney, B. Marais, L. Tarivonda.
Profile of tuberculosis patients with delayed sputum smear conversion in the Pacific island of Vanuatu ;
S. Fanai, K. Viney, L. Tarivonda, C. Roseveare, M. Tagaro, B. J. Marais.
Tuberculosis notifications, characteristics and treatment outcome: urban vs. rural Solomon Islands,
2000–2011 ; N. Itogo, P. C. Hill, K. Bissell, A. D. Harries, K. Viney, S. Gounder.
Sputum smear microscopy referral rates and turnaround time in the Tonga Islands ; L. Fonua, K. Bissell,
P. Vivili, S. Gounder, P. C. Hill.
Screening adult tuberculosis patients for diabetes mellitus in Ebeye, Republic of the Marshall Islands; J.
N. Nasa, R. Brostrom, S. Ram, A. M. V. Kumar, J. Seremai, M. Hauma, I. A. Paul, J. R. Langidrik.
Screening for tuberculosis and LTBI in diabetes patients, Pohnpei, Federated States of Micronesia ; R. R.
Defang, R. Brostrom, S. Ram, E. Johnson, P. S. Perman.
Public Health Rep. 2014 Jul;129(4):351-60.
Understanding the burden of tuberculosis among american indians/alaska natives in the u.s.: a
validation study.Podewils LJ, Alexy E, Driver SJ, Cheek JE, Holman RC, Haberling D, Brett M, McCray E,
Redd JT.
Scand J Infect Dis. 2014 Jul;46(7):533-6. doi: 10.3109/00365548.2014.898334. Epub 2014 Apr 22.
Joint failure after steroid therapy in tuberculous encephalitis.Ziskoven C, Richter J, Patzer T, Kircher J,
Krauspe R.
Thorax. 2014 Jun 26. [Epub ahead of print]
The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in
Greenland.Michelsen SW, Soborg B, Koch A, Carstensen L, Hoff ST, Agger EM, Lillebaek T, Sorensen HC,
Wohlfahrt J, Melbye M.
Trials . 2014 Jun 19;15(1):236. [Epub ahead of print]
Economic support to improve tuberculosis treatment outcomes in South Africa: a qualitative process
evaluation of a cluster randomized controlled trial.Lutge E, Lewin S, Volmink J.
Trans R Soc Trop Med Hyg. 2014 Jun 26. pii: tru082. [Epub ahead of print]
Tobacco smoking: a major risk factor for pulmonary tuberculosis - evidence from a cross-sectional study
in central India.Rao VG, Bhat J, Yadav R, Muniyandi M, Bhondeley MK, Sharada MA, Chadha VK, Wares
DF.
Trans R Soc Trop Med Hyg. 2014 Jul;108(7):402-7. doi: 10.1093/trstmh/tru066. Epub 2014 May 25.
Prevalence of extended treatment in pulmonary tuberculosis patients receiving first-line therapy and its
association with recurrent tuberculosis in Beijing, China.Xia Y, Goel S, Harries AD, Zhang Z, Gao T, Wang
L, Cheng S, Lin Y, Du X.
Profile and treatment outcome of smear-positive TB patients who failed to smear convert after 2
months of treatment in Nigeria.Ukwaja KN, Oshi DC, Oshi SN, Alobu I.
Tuberculosis (Edinb). 2014 Jul;94(4)
Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings
with a high burden of tuberculosis.Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, Jin X, Hong J, Li F, Mei J,
DeRiemer K, Gao Q.
Protective efficacy of piperine against Mycobacterium tuberculosis.Sharma S, Kalia NP, Suden P,
Chauhan PS, Kumar M, Ram AB, Khajuria A, Bani S, Khan IA.
A multicenter study of Cross-Priming Amplification for tuberculosis diagnosis at peripheral level in
China.Ou X, Song Y, Zhao B, Li Q, Xia H, Zhou Y, Pang Y, Wang S, Zhang Z, Cheng S, Liu C, Zhao Y.
Real time PCR quantification of viable Mycobacterium tuberculosis from sputum samples treated with
propidium monoazide.de Assunção TM, Batista EL Jr, Deves C, Villela AD, Pagnussatti VE, de Oliveira Dias
AC, Kritski A, Rodrigues-Junior V, Basso LA, Santos DS.
Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls.Kakkar AK, Dahiya N.
The role of ancestry in TB susceptibility of an admixed South African population.Daya M, van der Merwe
L, van Helden PD, Möller M, Hoal EG.
Antimicrobial peptides and proteins in mycobacterial therapy: Current status and future prospects.Padhi
A, Sengupta M, Sengupta S, Roehm KH, Sonawane A.
Vaccine. 2014 Jun 18. [Epub ahead of print]
Comparative performance of public and private sector delivery of BCG vaccination: Evidence from SubSaharan Africa.Wagner Z, Szilagyi PG, Sood N.
Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after
Mycobacterium tuberculosis infection.Trentini MM, de Oliveira FM, Nogueira Gaeti MP, Batista AC, Lima
EM, Kipnis A, Junqueira-Kipnis AP.
Vaccine. 2014 Jun 24;32(30):3759-64. doi: 10.1016/j.vaccine.2014.05.042. Epub 2014 May 20.
Causes of variation in BCG vaccine efficacy: Examining evidence from the BCG REVAC cluster randomized
trial to explore the masking and the blocking hypotheses.Barreto ML, Pilger D, Pereira SM, Genser B,
Cruz AA, Cunha SS, Sant'Anna C, Hijjar MA, Ichihara MY, Rodrigues LC.
Mycobacterium tuberculosis Strains of the Modern Sublineage of the Beijing Family Are More Likely To
Display Increased Virulence than Strains of the Ancient Sublineage.Ribeiro SC, Gomes LL, Amaral EP,
Andrade MR, Almeida FM, Rezende AL, Lanes VR, Carvalho EC, Suffys PN, Mokrousov I, Lasunskaia EB.
Vaccine. 2014 Jun 30;32(31):3982-8. doi: 10.1016/j.vaccine.2014.04.084. Epub 2014 May 9
Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.
Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom
WA, Johnson JL.
JOB OPPORTUNITIES
Nurse Practitioner
Olive View UCLA Medical Center Inpatient TB Unit, Los Angeles, California
Olive View-UCLA Medical Center (a unit of the Los Angeles County Department of Health Services) is
recruiting a Nurse Practitioner for inpatient TB unit. The NP will care for approximately 10-15 inpatients
(depending upon the unit census), in collaboration with our other NP, and will be supervised by the unit
attending infectious diseases physician. Daily responsibilities will include routine patient care,
medication monitoring and collaborative care interactions with nursing, dietary, and social work
personnel. The NP will work closely with infection control personnel to maintain isolation procedures
and will collaborate with LA County Public Health TB Control staff in establishing long-term patient
treatment plans. The nurse will also participate in infectious diseases outpatient clinic one half day per
week. We are also working to develop an outpatient LTBI clinic. In addition to these clinical duties, the
NP will assist with unit and hospital efforts to provide staff and patient education regarding TB.
Desirable qualifications include previous public health experience and interest in working with drugresistant TB patients; prior experience with substance abuse, correctional facilities, homelessness, HIV,
or psychiatric illness would be particularly useful. Interested applicants should contact Sylvia Anguiano
in the Dept of Medicine at Olive View-UCLA Medical Center and send a c.v. with letter of intent to:
Sylvia Anguiano, Dept of Medicine 2B182, Olive View-UCLA Medical Center, 14445 Olive View Drive
Sylmar, Ca. 91342
Office: 818-364-3205
E-mail [email protected]
COURSES/WORKSHOPS
FROM THE RTMCCs:
THE SOUTHEAST NATIONAL TB CENTER (SNTC)
http://sntc.medicine.ufl.edu/
Advanced Concepts in Pediatric TB - Introduction, Mycobacteriology, Pathogenesis and Epidemiology
Date: 8/14/2014 - 8/14/2014 Time: 12:00 PM - 1:00 PM Eastern Instructor/speaker: Ana Alvarez, MD
Format: Webinar
In part one of this 8-part series, the Pediatric ID Board Certifying Examination Content related to TB is
presented by expert speakers via case-based, interactive live webinars. The series goes beyond basic TB
concepts while following the pediatric ID guidelines. This session focuses on mycobacteriology,
pathogenesis and epidemiology.
Advanced Concepts in Pediatric TB: Latent TB Infection
Date: 9/11/2014 - 9/11/2014 Time: 12:00 PM - 1:00 PM Eastern Instructor/speaker: Nizar Maraqa, MD
Format: Webinar
In part one of this 8-part series, the Pediatric ID Board Certifying Examination Content related to TB is
presented by expert speakers via case-based, interactive live webinars. The series goes beyond basic TB
concepts while following the pediatric ID guidelines. This session focuses on latent TB infection.
Comprehensive Clinical TB Course
32.5 credit(s) 32.5 credit(s)Date: 10/6/2014 - 10/9/2014
Time: 8:00 AM - 5:30 PM Eastern Location: SNTC Cost: No Charge Format: Clinical course
This four-day intensive course will familiarize the clinician with all the aspects of tuberculosis infection,
disease and clinical care using an interdisciplinary and interactive approach. The curriculum is provided
through lecture, interactive case management sessions. The faculty is selected for their unique skill in
encouraging interaction and building rapport with participants. The atmosphere is relaxed with an
expectation that a free exchange of questions, comments and information will occur.
Tuberculin Skin Test Train-the-Trainer Course
7 credit(s)Date: 10/10/2014 - 10/10/2014
Time: 8:00 AM - 5:00 PM Eastern Location: SNTC Instructor/speaker: Ellen R Murray, BSN, RN
Cost: No Charge Format: Lecture/didactic
This one-day skill-building course provides the knowledge needed to plan, teach, and evaluate a
Mantoux Tuberculin Skin Test (TST) course. The course content includes skills for planning and
conducting a TST training, including adult learning principles and teaching strategies. The curriculum is
provided through lecture and participatory activities, including practicum in TST administration and
reading and instructional skills demonstration. Each participant must demonstrate proficiency in
delivering course content plus administering and reading the TST. Participants will receive feedback
from experienced trainers as they practice their skills. Topics include: adult learning principles for
instructors, tips and tools to plan and conduct a successful TST training, and TST course curriculum
review and demonstration.
THE RUTGERS GLOBAL TUBERCULOSIS INSTITUTE (GTBI)
Additional information for these and other upcoming trainings that are offered by the NJMS Global
Tuberculosis Institute can be found at: http://globaltb.njms.rutgers.edu/training/trainingcalendar.html
TB Intensive Workshop July 15-18, 2014 – Newark, NJ
Contact Anita Khilall at [email protected]
This workshop for clinicians provides comprehensive information on the principles and application of TB
diagnosis and treatment, as well as the management of TB in special populations. Topics will include
transmission and pathogenesis, diagnosis and treatment, drug resistance, TB-HIV co-infection, TB in
children and adolescents, and key aspects of patient management. Lectures, interactive discussions,
small group work and case studies will be used to enhance TB knowledge and clinical practice.
TB Contact Investigation Interviewing Workshop July 24 th and August 12-14, 2014 – Concord, NH
Contact Rajita Bhavaraju at [email protected]
The four-day training will cover all aspects of tuberculosis (TB) contact investigations through a variety
of didactic and role-playing practice sessions.
TB Intensive Workshop September 9-12, 2014 – Newark, NJ
Contact Jennifer K. Campbell at [email protected]
THE HEARTLAND TB CENTER
For more details and to check for open courses visit http://www.heartlandntbc.org/training.asp
The Impact of Substance Abuse and Mental Illness in Developing HIV and TB (An Online Course)
Contact: [email protected]
TB Nurse Case Management September 3, 10, 17, 24 (An Online Course)
C ontact: [email protected]
TB Nurse Case Management Oct 14-16, 2014 San Antonio, TX
Contact: [email protected]
Tuberculin Skin Test (TST) Practicum Oct 16, 2014 San Antonio, TX
Contact: [email protected]
TB Intensive Nov 11-14, 2014 San Antonio, TX
Contact: [email protected]
THE CURRY INTERNATIONAL TUBERCULOSIS CENTER
The Curry International Tuberculosis Center is pleased to announce that our 2014 Training Schedule is
now available, please visit: http://www.currytbcenter.ucsf.edu/training/schedule_2014.cfm .
Tuberculosis Clinical Intensive/LTBI Workshop, September 30-October 3, 2014 Oakland, CA
Pilot Four-day intensive for physicians and other licensed medical professionals who diagnose and treat
tuberculosis. Added: One-day LTBI Workshop pilot course. Details soon.
Tuberculosis Case Management and Contact Investigation Intensive November 18-21, 2014 Oakland,
CA Four-day training for nurses, communicable disease investigators, and medical social workers.
THE MAYO CLINIC CENTER FOR TUBERCULOSIS
Mayo Clinic Center for Tuberculosis - Home
Nursing Case Management, July 17 & 18, 2014 Springfield, Illinois
This one and a half-day intensive course was designed for nurses who are involved in the management
of patients with tuberculosis (TB), supervise those who provide care for TB patients, or are TB control
staff. In addition to health department staff, individuals who work in the following settings would
benefit from attending this workshop: hospital infection control, college or university health,
correctional facilities, long term care facilities, immigrant & refugee health, or practice in the
community. This course will familiarize attendees with an overview of tuberculosis infection, disease,
and clinical care using an interdisciplinary and interactive approach involving lectures and case
management sessions. centerfortuberculosis.mayo.edu
FROM NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
The 51st Annual Denver TB Course October 15-18, 2014 Denver, Colorado The purpose of this course is
to present this body of knowledge to general internists, public health workers, infectious diseases and
chest specialists, registered nurses, and other health care providers who will be responsible for the
management and care of patients with tuberculosis. For more information and to register, please call
800-844-2305 or visit The 51st Semi-A nnual Denver TB Course - National Jewish Health or call
800.844.2305
FROM THE UNION
The Union’s International Management Development Programme 2013 Courses : To register for any of
these courses, visit www.union-imdp.org or email [email protected] to receive more information.
Course fee for all courses includes lodging, breakfast, lunch, coffee and tea breaks, and course materials.
EVENTS, MEETINGS & CONFERENCES
Alphabetically listed by sponsoring organization
CONFERENCES
7th INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF TUBERCULOSIS DRUGS September
5, 1014 : Washington, DC
Registration for the 7th International Workshop on Clinical Pharmacology of Tuberculosis Drugs is open!
Do not miss this opportunity!. Register Now. Read More >>
AIDS 2014 - 20th International AIDS Conference
AIDS and HIV Medical Congress, Australia, Melbourne, 20 - 25 July 2014.
Renewing the Fight against TB: Transforming the Conversation to Win the Battle
Tuesday, 22 July, 1830-2030 Melbourne Room 2 Melbourne Convention and Exhibition Centre
Are we losing momentum in the fight against TB and AIDS?
Join the Stop TB Partnership for an informal and interactive conversation on amplifying the noise on TB,
rethinking our identity for the 21 st century and to present the work on the new Global Plan to Stop TB
2016-2010.
18th Annual United States Conference on AIDS (USCA)October 2-5, 2014, San Diego, California
AMERICAN PUBLIC HEALTH ASSOCIATION (APHA)
November 15-19 New Orleans, LA
2014 Annual Meeting registration now open as APHA heads to New Orleans
The theme of the meeting is Healthography: How Where you Live Affects Your Health and Well-being.
AMERICAN THORACIC SOCIETY (ATS)
Save the Dates: May 15-May 20, 2015 Denver, Colorado
The American Thoracic Society will celebrate 110 years of disseminating scientific discoveries and clinical
advances during the ATS 2015 International Conference. ATS 2015 will cover all aspects of pulmonary,
critical care, and sleep medicine, and its sessions, workshops, and more will highlight new findings that
are transforming the practice of medicine. Available online 10 May 2014
ASSOCIATION OF STATE AND TERRITORIAL HEALTH OFFICERS (ASTHO)
September 9-11 Albuquerque, New Mexico Learn More »
NATIONAL COUNCIL ON CORRECTIONAL HEALTH CARE (NCCHC)
National Conference on Correctional Health Care, October 20-22, 2014, Pre-conference Seminars
October 18-19, Las Vegas
http://www.ncchc.org/education-conferences-nationalconference-cfp.
PUBLIC HEALTH LAW CONFERENCE
October 16–17, 2014, in Atlanta, Georgia.
The conference will gather public health and legal experts from across the country to examine and
discuss today's critical challenges in public health law. Find more information about the conference and
learn how to get the early bird registration rate
THE UNION
45th UNION WORLD CONFERENCE ON LUNG HEALTH 28 October - 1 November 2014 Barcelona, Spain
Theme: Community-driven solutions for the next generation Click here to download the Barcelona 2014
Brochure
Website: http://barcelona.worldlunghealth.org
Email: [email protected]
Registration is now open for the year's most important tuberculosis conference – and the largest lung
health conference to focus on the issues as they affect low- and middle-income countries. Delegates
from 120 countries will gather in Barcelona, Spain for the 45th Union World Conference on Lung Health
on 28 October-1 November 2014. Read more.
NORTH AMERICAN REGION
19th ANNUAL CONFERENCE February 26-28, 2015 Vancouver, Canada
Click here to view the conference webpage
Deadline for abstract submission: Monday, October 6, 2014 We welcome the submission of abstracts
for poster and oral presentations of research on all aspects of tuberculosis control, including
epidemiologic, clinical, basic science, nursing, social, behavioural, psychosocial and educational studies,
as well as outcomes of program initiatives. Abstracts must be submitted in accordance with these
guidelines.
We are pleased to offer travel grants to selected individuals within the Americas and the Caribbean who
would otherwise be unable to attend the 19th Annual Conference of the Union - North America Region
without financial assistance. It is highly recommended that you seek additional sources of funding.
Deadline for Travel Grant Award submission: Monday, October 6, 2014